Metabolic cardiac protection is beneficial in patients undergoing coronary revascularization: Is it necessary afterwards?

Heart and Metabolism

Volumn , Issue 58, 2013, Pages 25-30

  Lopatin, Yury ^a  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Coronary artery bypass grafting (CABG); Metabolic cardioprotection; Percutaneous coronary intervention (PCI); Trimetazidine

Indexed keywords

TRIMETAZIDINE; TROPONIN I;

ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENERGY METABOLISM; EXERCISE TOLERANCE; FATTY ACID OXIDATION; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; LONG TERM CARE; MITOCHONDRIAL MEMBRANE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; SINGLE DRUG DOSE; ST SEGMENT ELEVATION;

EID: 84878330780     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) (2010) Guidelines on myocardial revascularization. Eur Heart J 31: 2501-2555
2. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al (2007) Outcomes associated with drugeluting and bare-metal stents: a collaborative network metaanalysis. Lancet 370:937-948 (Pubitemid 47393576)
3. Sabik JF III, Blackstone EH, Gillinov AM, Banbury MK, Smedira NG, Lytle BW (2006) Influence of patient characteristics and arterial grafts on freedom from coronary reoperation. J Thorac Cardiovasc Surg 131:90-98 (Pubitemid 43049788)
4. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG (2009) Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J Am Coll Cardiol 53: 232-241
5. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516 (Pubitemid 46588415)
6. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360: 2503-2515
7. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H (1960) Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 70: 68-78
8. Bulkely BH, Hutchins GM (1977) Myocardial consequences of coronary artery bypass graft surgery. The paradox of necrosis in areas of revascularization. Circulation 56: 906-913
9. Carden DL, Granger DN (2000) Pathophysiology of ischemia-reperfusion injury. J Pathol 190: 255-266
10. Hoffman JW, Gilbert TB, Poston RS, Silldorff EP (2004) Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol 36:391-411 (Pubitemid 40082893)
11. Moens AL, Claeyes MJ, Timmermans JP, Vrints CJ (2005) Myocardial ischemia/reperfusion injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100: 179-190
12. Ioannidis JP, Karvouni E, Katritsis DG (2003) Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42: 1406 -1411
13. Williams FM, Tanda K, Kus M, Williams T (1993) Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 22:828-833 (Pubitemid 23360404)
14. Tritto I, Ambrosio G (2005) The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 46:89-98 (Pubitemid 40917784)
15. Argaud L, Gomes L, Gateau-Roesch O (2005). Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 39: 983-899
16. Ruixing Y, Wenwu L, Al-Ghazali R (2007) Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemiareperfusion. Transl Res 149:152-160 (Pubitemid 46275573)
17. Kober G, Pennaforte S, Buck T (1993) Myocardial cytoprotection during percutaneous transluminal coronary angioplasty. Eur Heart J 14 (Suppl G): 6-l1
18. Steg PG, Grollier G, Gallay P, for the LIST Study Group (2001) A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 77:263-273 (Pubitemid 32155912)
19. Polonski L, Dec I, Wojnar R, Wilczek K (2002) Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin 18:389-396 (Pubitemid 35448535)
20. Bonello M, Sbragia P, Amabile N (2007) Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneus coronary intervention. Heart 93:703-707 (Pubitemid 46808271)
21. Fabiani JN, Ponzio O, Emerit I (1992) Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 23: 486-491
22. Vedrinne JM, Vedrinne C, Bompard D (1996) Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 82:712-718 (Pubitemid 26111564)
23. Tunerir B, Colak O, Alatas O (1999) Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 68:2173-2176 (Pubitemid 30027844)
24. Ruzyllo W, Szwed H, Sadowski Z (2004) Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 20:1447-1454 (Pubitemid 39361348)
25. Labrou A, Giannoglou G, Ziotas D (2007) Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 7:143-150 (Pubitemid 46790270)
26. Lopatin YM, Dronova EP (2010) Beneficial effects of long-term trimetazidine modified release therapy in patients having undergone coronary artery bypass grafting. Eur Heart J 31 (Abstract Suppl): 58
27. Lopatin YM, Dronova EP (2011) Beneficial effects of long-term trimetazidine modified release therapy in patients having undergone percutaneous coronary intervention. Eur Heart J 32 (Abstract Suppl): 569
28. Lionetti V, Stanley WC, Recchia FA (2011) Modulating fatty acid oxidation in heart failure. Cardiovasc Res 90: 202-209
29. Gao D, Ning N, Niu X, Hao G, Meng Zh (2011) Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart 97: 278-286